Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Investment analysts at SunTrust Banks boosted their FY2020 earnings estimates for shares of Regeneron Pharmaceuticals in a research report issued to clients and investors on Thursday. SunTrust Banks analyst Y. Suneja now forecasts that the biopharmaceutical company will post earnings of $19.07 per share for the year, up from their previous forecast of $18.97. SunTrust Banks has a “Hold” rating and a $435.00 price objective on the stock.
A number of other research firms have also recently issued reports on REGN. Leerink Swann reissued a “positive” rating and set a $552.00 target price (down from $580.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Friday, November 3rd. Piper Jaffray Companies reissued an “overweight” rating and set a $557.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, Guggenheim reissued a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $481.49.
Regeneron Pharmaceuticals (NASDAQ REGN) traded down $1.67 during midday trading on Monday, reaching $404.54. The company had a trading volume of 771,100 shares, compared to its average volume of 900,360. Regeneron Pharmaceuticals has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The company has a market cap of $43,460.00, a PE ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same period in the prior year, the business earned $3.13 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year.
In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 468 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $476.45, for a total transaction of $222,978.60. Following the transaction, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,335,218.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 88,942 shares of company stock worth $42,064,076 in the last quarter. Company insiders own 10.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of REGN. AQR Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 201.4% in the first quarter. AQR Capital Management LLC now owns 8,805 shares of the biopharmaceutical company’s stock worth $3,412,000 after purchasing an additional 5,884 shares during the period. Tudor Investment Corp ET AL bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $233,000. Fisher Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals by 75.1% in the second quarter. Fisher Asset Management LLC now owns 1,411 shares of the biopharmaceutical company’s stock worth $693,000 after purchasing an additional 605 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $642,000. Finally, Wendell David Associates Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $204,000. Institutional investors own 67.80% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.